达格列净在儿童慢性肾脏病中保护肾功能并减少白蛋白尿
这项多中心、随机、开放标签、终点盲法对照试验纳入114例非糖尿病慢性肾脏病1-4期儿童,比较达格列净联合标准治疗与单用标准治疗4个月的效果。达格列净组eGFR升高,对照组下降,组间差异为6.3 mL/min/1.73 m²(95%CI 2.1-10.5;p=0.004);UACR组间差异为-19.8 mg/g(95%CI -21.9至-18.6;p=0.002),未发生严重不良事件。
要点
- 达格列净组4个月eGFR升高2.1 mL/min/1.73 m²,对照组下降4.2 mL/min/1.73 m²。
- UACR较对照组显著下降,组间差异-19.8 mg/g(95%CI -21.9至-18.6)。
- 短期使用未发生严重不良事件,安全性可接受。
核心结论
- 达格列净与儿童非糖尿病慢性肾脏病短期肾功能轨迹改善及白蛋白尿减少相关,安全性可接受。
研究设计与样本
- 多中心、随机、开放标签、终点盲法对照试验,纳入114例慢性肾脏病1-4期儿童。
- 达格列净联合标准治疗组58例,单用标准治疗组56例,疗程4个月。
- 主要终点为eGFR和UACR变化,采用校正基线值的ANCOVA分析。
主要发现
- 4个月时达格列净组eGFR升高2.1 mL/min/1.73 m²,对照组下降4.2 mL/min/1.73 m²。
- eGFR组间差异为6.3 mL/min/1.73 m²(95%CI 2.1-10.5;p=0.004)。
- UACR组间差异为-19.8 mg/g(95%CI -21.9至-18.6;p=0.002)。
- 早期慢性肾脏病阶段可见白蛋白尿分类向更低类别转移。
- 未发生严重不良事件。
关键数值与推荐
- eGFR组间差异6.3 mL/min/1.73 m²(95%CI 2.1-10.5;p=0.004)。
- UACR组间差异-19.8 mg/g(95%CI -21.9至-18.6;p=0.002)。
临床怎么用
- 对非糖尿病慢性肾脏病1-4期儿童,可考虑在标准治疗基础上加用达格列净以改善短期肾功能轨迹并减少白蛋白尿。
- 用药期间关注肾功能与白蛋白尿变化,并监测不良事件。
局限性
- 开放标签设计,仅终点盲法。
- 随访仅4个月,缺乏长期肾脏结局数据。
- 样本量114例,为非糖尿病慢性肾脏病儿童的单一人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce CKD progression in adults; but pediatric evidence remains limited. We evaluated dapagliflozin in children with non-diabetic CKD. METHODS: In this multicenter, randomized, open-label, endpoint-blinded controlled trial, 114 children with CKD stages 1-4 were assigned to dapagliflozin plus standard care (n=58) or standard care alone (n=56) for 4 months. Primary outcomes were changes in estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), analyzed using ANCOVA adjusted for baseline values. RESULTS: Baseline characteristics were comparable between groups. At 4 months, eGFR increased in the dapagliflozin group (+2.1 mL/min/1.73 m²) and declined in controls (-4.2 mL/min/1.73 m²), yielding a between-group difference of 6.3 mL/min/1.73 m² (95% CI 2.1-10.5; p=0.004). UACR decreased significantly with dapagliflozin versus control (between-group difference -19.8 mg/g (95% CI: -21.9 to -18.6; p=0.002). Early CKD stages showed a shift toward lower albuminuria categories. No serious adverse events occurred. CONCLUSION: Dapagliflozin was associated with short-term improvement in kidney function trajectory and reduction in albuminuria in children with CKD, with an acceptable safety profile.
引用
- Assadi F, Bidabadi E, Mazaheri M, et al. Dapagliflozin preserves kidney function and reduces albuminuria in children with chronic kidney disease. Nephrol Dial Transplant. 2026. PMID: 42560379. doi:10.1093/ndt/gfag177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。